Published in Int J Mol Sci on June 23, 2016
Silencing salusin-β attenuates cardiovascular remodeling and hypertension in spontaneously hypertensive rats. Sci Rep (2017) 0.75
Relationship and associated mechanisms between ambulatory blood pressure and clinic blood pressure with prevalent cardiovascular disease in diabetic hypertensive patients. Medicine (Baltimore) (2017) 0.75
Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications. Neurotox Res (2017) 0.75
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
Molecular mechanisms of human hypertension. Cell (2001) 11.17
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med (2007) 9.51
Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2008) 6.48
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA (2015) 4.63
Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA (1996) 4.31
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 4.20
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 4.10
Fibrosis--a common pathway to organ injury and failure. N Engl J Med (2015) 3.94
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol (2002) 2.94
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest (1994) 2.81
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation (2002) 2.81
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res (2005) 2.79
Weight loss and the renin-angiotensin-aldosterone system. Hypertension (2005) 2.58
A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab (2008) 2.48
Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev (2004) 2.36
Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol (2011) 2.29
CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol (2000) 2.25
Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res (2005) 2.24
Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev (2011) 2.22
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res (2012) 2.08
Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol (2000) 2.07
The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med (1981) 2.05
Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab (2000) 2.00
Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol (1994) 1.91
Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J (2006) 1.90
Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci U S A (2015) 1.85
The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol (2013) 1.76
Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A (2003) 1.74
Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A (2012) 1.74
Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol (2005) 1.73
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci (1992) 1.65
Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J (1966) 1.58
Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. Hypertension (2014) 1.56
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Primary aldosteronism and hypertensive disease. Hypertension (2003) 1.49
Chronic kidney disease progression. J Am Soc Nephrol (2006) 1.40
Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med (2006) 1.31
Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab (2009) 1.30
The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol (2012) 1.24
Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res (2003) 1.22
Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res (2015) 1.22
A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab (2012) 1.20
Mechanisms of salt and water retention in congestive heart failure. The importance of aldosterone. Am J Med (1960) 1.19
Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension (2000) 1.19
Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology (2007) 1.18
Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res (2009) 1.17
Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension (2004) 1.17
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol (2011) 1.17
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology (2007) 1.15
Metabolic risk factors and renal disease. Kidney Int (2007) 1.14
Functional effects of rho-kinase-dependent phosphorylation of specific sites on cardiac troponin. Circ Res (2005) 1.14
The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflam (2014) 1.13
Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem (1991) 1.13
Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol (2004) 1.11
Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl (2011) (2014) 1.11
Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension (2002) 1.08
Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res (2011) 1.08
Aldosterone and arterial hypertension. Nat Rev Endocrinol (2009) 1.06
The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin (2010) 1.04
Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens (1999) 1.03
Mineralocorticoid receptor blockade improves diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2011) 1.02
Angiotension-(1-7) and antihypertensive mechanisms. J Nephrol (1999) 1.02
Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension (2011) 1.01
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med (2012) 0.99
Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension (2002) 0.98
Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens (2010) 0.98
Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol (2014) 0.98
Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res (2008) 0.97
Endothelin-1 inhibits sodium reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct. Am J Physiol Renal Physiol (2013) 0.97
Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism. J Nutr (2002) 0.97
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol (2008) 0.96
Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis (2008) 0.96
Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol (2005) 0.96
Endothelin-1 expression in vascular adventitial fibroblasts. Am J Physiol Heart Circ Physiol (2005) 0.96
Aldosterone in clinical medicine; past, present, and future. AMA Arch Intern Med (1956) 0.94
Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation (2003) 0.94
Prorenin and the (pro)renin receptor--an update. Nephrol Dial Transplant (2007) 0.94
Regulation of the human Na/K-ATPase beta1 gene promoter by mineralocorticoid and glucocorticoid receptors. J Biol Chem (1998) 0.94
Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension (2014) 0.93
Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension (2001) 0.93
Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris) (2000) 0.93
Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail (2015) 0.93
Anti-macrophage migration inhibitory factor reduces transforming growth factor-beta 1 expression in experimental IgA nephropathy. Nephrol Dial Transplant (2004) 0.92
Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes (2002) 0.91
Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens (2010) 0.90
Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab (2004) 0.90
The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int (2000) 0.90
Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res (2015) 0.90
Local Control of Aldosterone Production and Primary Aldosteronism. Trends Endocrinol Metab (2016) 0.87